| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effect of valsartan on the incidence of diabetes and cardiovascular events.
|
N Engl J Med
|
2010
|
5.46
|
|
2
|
The metabolic syndrome and chronic kidney disease in U.S. adults.
|
Ann Intern Med
|
2004
|
5.45
|
|
3
|
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.
|
Circulation
|
2006
|
4.61
|
|
4
|
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
|
N Engl J Med
|
2010
|
4.38
|
|
5
|
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.
|
Diabetes Care
|
2007
|
4.30
|
|
6
|
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
|
Ann Intern Med
|
2010
|
3.56
|
|
7
|
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
|
Circulation
|
2003
|
3.22
|
|
8
|
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
|
JAMA
|
2004
|
3.20
|
|
9
|
Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring.
|
Diabetes Care
|
2003
|
3.08
|
|
10
|
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.
|
Diabetes Care
|
2004
|
3.00
|
|
11
|
Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
|
Diabetes Care
|
2010
|
2.42
|
|
12
|
Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults.
|
Diabetes Care
|
2010
|
2.38
|
|
13
|
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
|
Lancet
|
2012
|
2.13
|
|
14
|
Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease.
|
Diabetes Care
|
2007
|
1.95
|
|
15
|
Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).
|
Am J Cardiol
|
2005
|
1.83
|
|
16
|
Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists.
|
Endocr Pract
|
2008
|
1.80
|
|
17
|
Hypoglycemia, diabetes, and cardiovascular events.
|
Diabetes Care
|
2010
|
1.78
|
|
18
|
Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices.
|
Pharmacoeconomics
|
2010
|
1.70
|
|
19
|
Insulin resistance and risk of chronic kidney disease in nondiabetic US adults.
|
J Am Soc Nephrol
|
2003
|
1.70
|
|
20
|
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
|
Ann Intern Med
|
2013
|
1.68
|
|
21
|
Body weight changes with beta-blocker use: results from GEMINI.
|
Am J Med
|
2007
|
1.60
|
|
22
|
Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis.
|
Health Qual Life Outcomes
|
2010
|
1.60
|
|
23
|
Cardiovascular effects of insulin sensitizers in diabetes.
|
Curr Opin Investig Drugs
|
2006
|
1.55
|
|
24
|
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes.
|
Hypertension
|
2005
|
1.54
|
|
25
|
Beyond the monofilament for the insensate diabetic foot: a systematic review of randomized trials to prevent the occurrence of plantar foot ulcers in patients with diabetes.
|
Diabetes Care
|
2011
|
1.49
|
|
26
|
Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.
|
Diabetes Care
|
2014
|
1.47
|
|
27
|
Metabolic memory in diabetes--focus on insulin.
|
Diabetes Metab Res Rev
|
2005
|
1.43
|
|
28
|
ROLE OF INSULIN SENSITIZERS ON CARDIOVASCULAR RISK FACTORS IN POLYCYSTIC OVARIAN SYNDROME: A META-ANALYSIS.
|
Endocr Pract
|
2015
|
1.39
|
|
29
|
Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.
|
Circulation
|
2014
|
1.32
|
|
30
|
The Hurricane Katrina aftermath and its impact on diabetes care: observations from "ground zero": lessons in disaster preparedness of people with diabetes.
|
Diabetes Care
|
2006
|
1.31
|
|
31
|
Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion.
|
J Diabetes Complications
|
2009
|
1.26
|
|
32
|
Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III).
|
Ann Epidemiol
|
2004
|
1.21
|
|
33
|
Relationship between HbA1c level and peripheral arterial disease.
|
Diabetes Care
|
2005
|
1.20
|
|
34
|
Cardiovascular disease risk of abdominal obesity vs. metabolic abnormalities.
|
Obesity (Silver Spring)
|
2010
|
1.18
|
|
35
|
Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes.
|
Diabetes Care
|
2012
|
1.15
|
|
36
|
Narrative review: hepatobiliary disease in type 2 diabetes mellitus.
|
Ann Intern Med
|
2004
|
1.13
|
|
37
|
Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes.
|
Diabetes Care
|
2006
|
1.13
|
|
38
|
Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).
|
Diabetes Care
|
2013
|
1.10
|
|
39
|
Therapeutic targets to reduce cardiovascular disease in type 2 diabetes.
|
Nat Rev Drug Discov
|
2009
|
1.04
|
|
40
|
The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients.
|
J Diabetes Complications
|
2012
|
1.03
|
|
41
|
Therapeutic approaches to target inflammation in type 2 diabetes.
|
Clin Chem
|
2010
|
1.03
|
|
42
|
Overview of metformin: special focus on metformin extended release.
|
Expert Opin Pharmacother
|
2012
|
1.02
|
|
43
|
Redefining the diagnosis of diabetes using glycated hemoglobin.
|
Diabetes Care
|
2009
|
1.00
|
|
44
|
Translating the A1C Assay.
|
Diabetes Care
|
2008
|
1.00
|
|
45
|
Bile acid sequestrants for lipid and glucose control.
|
Curr Diab Rep
|
2010
|
0.96
|
|
46
|
Cardiovascular benefits of exogenous insulin.
|
J Clin Endocrinol Metab
|
2012
|
0.95
|
|
47
|
Differential association of birth weight with cardiovascular risk variables in African-Americans and Whites: the Bogalusa heart study.
|
Ann Epidemiol
|
2004
|
0.93
|
|
48
|
Cardiovascular events and insulin therapy: a retrospective cohort analysis.
|
Diabetes Res Clin Pract
|
2008
|
0.92
|
|
49
|
Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).
|
Am J Cardiol
|
2005
|
0.91
|
|
50
|
Management of diabetes mellitus in patients with cardiovascular disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
|
Circulation
|
2010
|
0.90
|
|
51
|
ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association.
|
J Am Coll Cardiol
|
2009
|
0.88
|
|
52
|
Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus.
|
J Diabetes Complications
|
2010
|
0.88
|
|
53
|
Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet.
|
Curr Med Res Opin
|
2003
|
0.87
|
|
54
|
Drugs affecting homocysteine metabolism: impact on cardiovascular risk.
|
Drugs
|
2002
|
0.87
|
|
55
|
Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse!
|
Diabetes Care
|
2007
|
0.87
|
|
56
|
Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors.
|
Curr Diab Rep
|
2010
|
0.87
|
|
57
|
Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.
|
BMC Psychiatry
|
2009
|
0.86
|
|
58
|
Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension.
|
J Diabetes Complications
|
2008
|
0.86
|
|
59
|
The effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on oxidative enzymes in adipocytes and liver.
|
Toxicology
|
2002
|
0.86
|
|
60
|
Racial disparity of eye examinations among the U.S. working-age population with diabetes: 2002-2009.
|
Diabetes Care
|
2014
|
0.84
|
|
61
|
Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial.
|
J Am Soc Hypertens
|
2009
|
0.84
|
|
62
|
Association between hypoglycemia and fall-related events in type 2 diabetes mellitus: analysis of a U.S. commercial database.
|
J Manag Care Spec Pharm
|
2015
|
0.83
|
|
63
|
The impact of antidiabetic therapies on cardiovascular disease.
|
Curr Atheroscler Rep
|
2005
|
0.83
|
|
64
|
The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.
|
Diabetes Care
|
2013
|
0.82
|
|
65
|
Physician practice behavior and practice guidelines: using unannounced standardized patients to gather data.
|
J Gen Intern Med
|
2008
|
0.82
|
|
66
|
Time to recovery in diabetes and comorbidities following Hurricane Katrina.
|
Disaster Med Public Health Prep
|
2010
|
0.82
|
|
67
|
Urinary catalytic iron in obesity.
|
Clin Chem
|
2010
|
0.82
|
|
68
|
Saxagliptin overview: special focus on safety and adverse effects.
|
Expert Opin Drug Saf
|
2012
|
0.82
|
|
69
|
Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
|
Vascul Pharmacol
|
2006
|
0.82
|
|
70
|
Economic burden of hypoglycemia in patients with Type 2 diabetes.
|
Expert Rev Pharmacoecon Outcomes Res
|
2012
|
0.81
|
|
71
|
Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial.
|
Clin Chem
|
2010
|
0.81
|
|
72
|
Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1).
|
Diabetes Care
|
2012
|
0.81
|
|
73
|
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.
|
J Clin Hypertens (Greenwich)
|
2007
|
0.79
|
|
74
|
ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association.
|
Circulation
|
2009
|
0.79
|
|
75
|
Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin.
|
Metab Syndr Relat Disord
|
2006
|
0.79
|
|
76
|
Metabolic syndrome: underrated or underdiagnosed?
|
Diabetes Care
|
2005
|
0.79
|
|
77
|
ASSOCIATION BETWEEN HYPOGLYCEMIA AND FALL-RELATED FRACTURES AND HEALTH CARE UTILIZATION IN OLDER VETERANS WITH TYPE 2 DIABETES.
|
Endocr Pract
|
2015
|
0.78
|
|
78
|
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study.
|
J Cardiometab Syndr
|
2008
|
0.78
|
|
79
|
Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND.
|
J Diabetes Complications
|
2013
|
0.78
|
|
80
|
Effects of the thiazolidinediones on cardiovascular risk factors.
|
Am J Cardiovasc Drugs
|
2002
|
0.77
|
|
81
|
Healthcare resource utilization, adherence and persistence with antipsychotic therapy among schizophrenia patients with vs. without pre-existing metabolic syndrome.
|
Curr Med Res Opin
|
2010
|
0.77
|
|
82
|
Metabolic syndrome and heart failure.
|
Heart Fail Clin
|
2006
|
0.77
|
|
83
|
Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes.
|
Diabetes Metab Syndr Obes
|
2009
|
0.77
|
|
84
|
Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
|
Endocr Pract
|
2012
|
0.77
|
|
85
|
Economic burden of hypoglycemia with basal insulin in type 2 diabetes.
|
Am J Manag Care
|
2017
|
0.76
|
|
86
|
Empirical derivation to improve the definition of the metabolic syndrome in the evaluation of cardiovascular disease risk.
|
Diabetes Care
|
2011
|
0.76
|
|
87
|
Comparing diabetes drugs--helping clinical decisions?
|
Lancet
|
2012
|
0.76
|
|
88
|
Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes.
|
J Diabetes Complications
|
2013
|
0.75
|
|
89
|
Case-based study: from prediabetes to complications--opportunities for prevention.
|
PLoS Med
|
2005
|
0.75
|
|
90
|
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial and Hurricane Katrina: lessons for managing clinical trials during and after a natural disaster.
|
Contemp Clin Trials
|
2008
|
0.75
|
|
91
|
The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial.
|
J Diabetes Complications
|
2005
|
0.75
|
|
92
|
Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?
|
Expert Rev Clin Pharmacol
|
2012
|
0.75
|
|
93
|
Challenges to the diagnosis, evaluation, treatment, and management of clustered cardiometabolic risk factors.
|
J Cardiometab Syndr
|
2008
|
0.75
|
|
94
|
REVISITING THE USE OF PIOGLITAZONE IN THE TREATMENT OF TYPE 2 DIABETES.
|
Endocr Pract
|
2016
|
0.75
|
|
95
|
Pancreas transplantation--a controversy in evolution.
|
J La State Med Soc
|
2008
|
0.75
|
|
96
|
Predictors of duloxetine versus other treatments among veterans with diabetic peripheral neuropathic pain: a retrospective study.
|
Pain Pract
|
2011
|
0.75
|
|
97
|
Retraction notice to "Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study".
|
J Diabetes Complications
|
2017
|
0.75
|
|
98
|
Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome.
|
Metab Syndr Relat Disord
|
2005
|
0.75
|
|
99
|
The long-term survival of simultaneous pancreas and kidney transplant with basiliximab induction therapy.
|
Clin Transplant
|
2007
|
0.75
|
|
100
|
Diabetes: advances and controversies.
|
Clin Chem
|
2010
|
0.75
|